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ORIGINAL RESEARCH
Study objective: To determine the extent of intravenous (IV) antibiotic use for community-
acquired pneumonia (CAP) in emergency departments, the practice patterns in seven emergency
departments serving the adult residents of one Canadian city were observed.
Methods: An observational study of nonhospitalized adults diagnosed with CAP in seven
emergency departments was conducted between November 15, 2000, and November 19, 2002.
Data related to antibiotic treatment of CAP administered in the emergency department and
patient-specific characteristics potentially predictive of IV treatment were collected.
Results: A total of 3512 subjects were identified, of which 4.9% received treatment with IV
antibiotics. Cefuroxime and levofloxacin were the most commonly used IV agents, while
orally-treated subjects primarily received a macrolide or levofloxacin. The proportion of
subjects receiving IV antibiotics differed significantly among the seven sites: 1.4%–10.6%
(p < 0.0001). Logistic regression identified a number of independent predictors of receipt of
IV antibiotics including risk class, temperature, respiratory rate, study year, presence of
vomiting, prior antibiotic treatment, and personal care home residence. However, these
predictors did not explain intersite differences.
Conclusion: Only a small proportion of patients (4.9%) presenting to the emergency
department with CAP received IV antibiotics. While patient demographics and severity
indicators influenced the likelihood of receipt of IV antibiotics, considerable intersite variation
existed, despite adjustment for such factors.
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Introduction
Community-acquired pneumonia (CAP) is a common infection with a reported
incidence of between 1 and 12 episodes per 1000 persons per year, resulting in
considerable morbidity, mortality, and healthcare costs (Marrie 1998).
 Guidelines
for the management of CAP are widely available (Bartlett et al 2000; Mandell et al
2000); however, variation between recommended and actual practice is frequently
reported (Gleason et al 1997; Fantin et al 2001). Practice patterns previously studied
have included choice of antibiotic, rates of hospitalization, and length of stay (Gilbert
et al 1998; Menendez et al 2001; Battleman et al 2002; Jin et al 2003). Variations in
the route of antibiotic treatment, especially among outpatients, have received little
attention, despite the considerable cost implications of intravenous (IV) treatment.
Current Canadian treatment guidelines do not make specific recommendations
regarding route of treatment, except for patients requiring admission to the intensive
care unit (Mandell et al 2000). However, patients at low risk treated on an outpatient
basis receive predominantly oral antibiotics, while the majority of higher risk
hospitalized subjects initially receive intravenously administered antibiotics (Gilbert
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et al 1998). While oral treatment is the norm among
nonhospitalized patients, there is some support for initial
treatment with parenteral antibiotics in the emergency
department (ED) followed by oral administration (Moran
2001). The extent of this practice is unknown. We examined
the extent and predictors of initial receipt of IV-administered
antibiotics for CAP in EDs in one Canadian city.
Methods
This observational descriptive study was conducted at seven
EDs that were associated with six hospitals and one
community-care center, and service the needs of
approximately 860 000 residents of one Canadian city and
surrounding areas. The study was approved by the Health
Research Ethics Board of the university with which both
authors are affiliated.
Beginning November 15, 2000, a “pneumonia critical
pathway” was implemented at all seven sites in the region
(see below). Patients 17 years of age or older were enrolled
into the pathway if they presented to one of the study
hospitals and were clinically diagnosed with community-
acquired pneumonia based on two or more of the following
symptoms: fever, cough, dyspnea, pleuritic chest pain,
crackles, and findings of consolidation on chest examination
plus an opacity on chest radiography (as interpreted by the
attending physician). Patients were excluded from the
pathway if they had physician-diagnosed or suspected
aspiration pneumonia, tuberculosis, cystic fibrosis, were
immunosuppressed (eg, human immunodeficiency virus
infection, use of greater than 10 mg per day of prednisone
for more than one month or other immunosuppressive
agents, active treatment for cancer, history of organ
transplantation), pregnant or nursing, or if they required
direct admission to the intensive care unit.
Based on our previously published work (Marrie et al
2000), a validated “critical pathway” for the management
of pneumonia was developed with the goal of improving
the quality and efficiency of care. A multidisciplinary team
consisting of infectious disease specialists, general internists,
respirologists, emergentologists, family physicians,
pharmacists, nurses, respiratory therapists, and dieticians
developed and implemented the pathway at all regional
hospitals. Patients were evaluated and the “pneumonia
severity of illness” score was calculated and risk class
assigned using the patient’s age, sex, comorbid illnesses,
physical findings, and laboratory results (Fine et al 1997).
For patients who were to be discharged from the ED,
antibiotic therapy in accordance with published guidelines
was recommended (Mandell et al 2000). No
recommendation was made regarding IV antibiotic therapy
for those who were to be treated on an ambulatory basis.
Indeed oral antibiotic therapy was recommended for
inpatients unless there was vomiting or hypotension.
Triage is defined as the “initial clinical assessment of
patients” and is a term most often applied to patients assessed
in the ED. Triage staff sort and prioritize patients for urgency
of care based on information obtained at the time of
presentation. Different triage systems have been developed,
and, in Canada, the Canadian Triage and Acuity Scale
(CTAS) is the nationally recognized standard for triage. This
5-point scoring system grades patients from resuscitation
(1) to deferrable (5) and is widely employed.
Research nurses were responsible for reviewing
admission and ED discharge data on a daily (Monday to
Friday) basis to identify all potential admitted or discharged
CAP cases. They performed retrospective data collection
using standardized case report forms. Data collection
included, time of presentation to the ED, antibiotic(s)
administered, and route and time of administration. Patient
variables of interest included demographic data (eg, age,
gender, personal care home residence), physical status (eg,
presence of nausea or vomiting), physiologic data (eg,
temperature, respiratory rate), previous treatment (eg, repeat
visit for the same indication, antibiotic treatment in previous
seven days), and triage score. In addition, risk class was
assigned as described above. Data collection began
November 15, 2000, and ended November 19, 2002.
Statistical methods
Univariate differences between IV and non-IV treated
outpatients were assessed using Pearson chi-square and
Wilcoxon rank sum tests as appropriate. Logistic regression
was used to model the effects of site of care and patient
characteristics on the probability of receipt of IV antibiotics.
All potential explanatory variables were entered into the
logistic model regardless of their statistical significance in
univariate testing. Due to low numbers of subjects with triage
scores of 1 or 5, levels of this severity-related variable were
collapsed and reclassified as “high” (triage score = 1 or 2),
“moderate” (triage score = 3), and “low” (triage score = 4
or 5). Subjects with missing triage scores were assigned the
median based on treatment assignment (median = 3 for both
IV and non-IV treated patients). Subjects with missing time
of presentation were assumed to have presented during the
day. Refinement of the model was accomplished by stepwise
removal of the least significant contributor, with minimumTherapeutics and Clinical Risk Management 2005:1(1) 51
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significance at the 0.05 level. The reduced, or parsimonious
model, is reported with the effect of explanatory variables
on the probability of receipt of an intravenous antibiotic
reported as odds ratios with associated 95% confidence
intervals. Statistical analysis was performed using Statistical
Analysis System software version 8.2 (SAS Institute Inc,
Cary, NC, USA).
Results
A total of 6515 potentially eligible subjects presented to
the seven EDs, of which 3003 (46.1%) were initially
admitted and 3512 (53.9%) were treated as outpatients
(Table 1). Further, among outpatients, 173 (4.9%) received
treatment with IV antibiotics, 1523 (43.4%) received oral
antibiotic treatment, and 1816 (51.7%) received no antibiotic
treatment during the ED stay. Among IV-treated subjects,
59.0% received a single antibiotic, 39.3% received two
antibiotic agents, and 2.0% received three or more different
antibiotics. Among IV-treated subjects receiving a single
antibiotic, levofloxacin (44.1%) and cefuroxime (41.2%)
were most commonly administered. For those IV-treated
subjects receiving two antibiotics during the ED stay,
cefuroxime plus a macrolide (erythromycin, clarithromycin,
or azithromycin) (72.1%) and cefuroxime plus levofloxacin
(10.3%) combinations were most commonly observed.
Greater than 99% of subjects receiving oral antibiotics were
treated with a single agent, of which macrolides
(erythromycin, clarithromycin, or azithromycin) (57.6%)
and levofloxacin (39.7%) were the most commonly
prescribed. Median time to discharge from the ED varied
significantly between treatments; no treatment (2.9 hours),
oral antibiotic (4.1 hours), and IV antibiotic (6.0 hours)
(p < 0.0001). For subjects receiving antibiotic treatment
there was no significant difference in the time to receipt of
antibiotic agent; oral (3.2 hours), IV (3.4 hours) (p = 0.76).
The proportion of subjects receiving IV antibiotics varied
significantly with risk class; I (2.9%), II (4.7%), III (5.6%),
IV (7.3%), V (17.2%) (p < 0.0001). Subjects receiving IV
antibiotics were significantly more likely to reside in
personal care homes, have a recent history of vomiting, and
have higher severity of illness, as indicated by triage score
(Table 2). Differences in vital signs (eg, heart rate,
respiratory rate) were also evident between IV and non-IV
treated patients. Time of day of presentation to the ED had
no effect on the likelihood of receipt of IV antibiotics.
Among outpatients, the proportion of subjects receiving
IV antibiotics varied among sites from 1.4% to 10.6%
(Table 1). The site with the highest proportion of IV
antibiotic use (site A) was a “free-standing” ED not housed
within an acute care hospital. There was considerable
overlap in the physicians staffing this site and those staffing
the ED with the second highest use of IV antibiotics (site B).
A total of 506 (92.8%) of the 545 outpatients presenting to
site A and 388 (49.5%) of 784 outpatients presenting to
site B were treated by physicians staffing both sites. In an
examination of only those 894 subjects treated by the
overlapping physicians significant differences in receipt of
IV antibiotics remained between the two sites; site A (11.1%)
and site B (7.2%) (p = 0.05). Overall, the likelihood of
receipt of IV antibiotics decreased during the study period
from 6.9% in year one to 3.0% in year two, and decreases
were observed at all seven sites.
The multivariable model identified a number of
independent predictors of receipt of IV antibiotics (Table 3).
For example, personal care home residence and receipt of
an antibiotic within the previous seven days increased the
probability approximately fivefold and twofold, respectively.
Higher temperature and respiratory rate were independently
associated with receipt of the agents of interest, as was a
recent history of vomiting. In addition, subjects in the highest
Table 1 Initial treatment of subjects with community-acquired pneumonia (CAP) presenting to seven emergency departments
All CAP CAP patients CAP patients Proportion of outpatients
patients admitted to hospital treated as outpatients receiving IV antibiotics
Site N N % N % N %
a
A 669 124 18.5 545 81.5 58 10.6
B 1769 985 55.7 784 44.3 57 7.3
C 1003 590 58.8 413 41.2 20 4.8
D 828 328 39.6 500 60.4 14 2.8
E 460 153 33.3 307 66.7 5 1.6
F 871 393 45.1 478 54.9 12 2.5
G 915 430 47.0 485 53.0 7 1.4
Total 6515 3003 46.1 3512 53.9 173 4.9
a Percentage is of those treated as outpatients.
Abbreviations: CAP, community-acquired pneumonia; IV, intravenous.Therapeutics and Clinical Risk Management 2005:1(1) 52
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severity and risk classes were significantly more likely to
receive IV antibiotics compared with those in the lowest
severity and risk classes. Variables unrelated to patient
demographics and severity of illness were also associated
with receipt of IV antibiotics. For example, subjects
presenting to EDs in the second year of the study had a
decreased odds of receipt of IV treatment, while site of care
continued to predict such treatment despite controlling for
patient demographics and severity indicators. Odds of
receipt of IV antibiotics at the site with the highest use was
14.2 times that at the site with the lowest use of IV antibiotics
for CAP patients.
Discussion
In the current study, only a small proportion (approximately
5%) of patients with CAP presenting to EDs and treated on
an ambulatory basis received treatment with IV antibiotics.
Antibiotic agents received by orally-treated subjects were
primarily those recommended for outpatients in published
treatment guidelines (eg, erythromycin, clarithromycin, or
azithromycin) (Mandell et al 2000). In contrast, IV-treated
subjects received agents consistent with recommendations
for inpatients; eg, cefuroxime plus a macrolide
(erythromycin, clarithromycin, or azithromycin) and
levofloxacin alone (Mandell et al 2000).
In addition to site of care, multivariable analysis
identified a number of independent predictors of receipt of
IV antibiotics. The positive association of patient variables,
such as inability to tolerate oral medications (eg, history of
vomiting) and higher temperature and respiratory rate, with
receipt of IV antibiotics suggests such treatment was being
reserved for more acutely ill outpatients. The positive
Table 2 Characteristics of 3512 outpatients with community-acquired pneumonia: comparison by emergency department
treatment
No/oral antibiotic IV antibiotic
(N=3339) (N=173)
Patient variables N % N % P-value
Age in years (median) 47.7 45.4 0.31
Female gender  1534 45.9 71 41.0 0.21
Personal care home residence 74 2.2 19 11.0 < 0.0001
Antibiotic use in last 7 days 588 17.6 40 23.1 0.07
Sought care for CAP last 7 days 572 17.1 34 19.7 0.39
Nausea 407 12.2 26 15.0 0.27
Vomiting 381 11.4 37 21.4 < 0.0001
Temperature °C (median) 37.1 37.9 < 0.0001
Heart rate – beats/minute (median) 93.0 101.0 < 0.0001
Respirations per minute (median) 20.0 24.0 < 0.0001
Diastolic BP (mmHg) (median) 78.0 72.0 < 0.0001
Systolic BP (mmHg) (median) 129.0 125.0 < 0.05
Risk Class  < 0.0001
I 665 19.9 20 11.6
II 1833 54.9 90 52.0
III 473 14.2 28 16.2
IV 320 9.6 25 14.5
V 48 1.4 10 5.8
Triage Score p < 0.0005a
1 1 0.03 1 0.6
2 142 4.3 14 8.1
3 1529 45.8 81 46.8
4 1290 38.6 41 23.7
5 66 2.0 4 2.3
Not documented 311 9.3 32 18.5
Time of day 0.32
b
Day (08:00–16:00 hours) 1232 36.9 71 41.0
Evening (16:01–24:00 hours) 1429 42.8 65 37.6
Night (00:01–07:59 hours) 472 14.1 28 16.2
Not documented 206 6.2 9 5.2
a Excludes those “not documented” and collapsed categories of triage scores into 3 severity levels (high; triage = 1 or 2, moderate; triage = 3, low; triage = 4 or 5).
b Excludes those “not documented”.
Abbreviations: CAP, community-acquired pneumonia; IV, intravenous.Therapeutics and Clinical Risk Management 2005:1(1) 53
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associations between more comprehensive measures of
severity of illness, such as the risk class and triage score,
with receipt of IV antibiotics was not unexpected. Similarly,
the increased likelihood of receipt of IV treatment among
personal care home residents suggests conservative care in
light of the possible ramifications of inadequate treatment
among this patient population.
Modest variations in the use of IV antibiotics among
outpatients were evident among the seven sites. The highest
proportion of outpatients receiving IV agents (10.6%) was
observed at site A. The lack of available inpatient beds at
site A (free-standing ED) may have been a factor in the
decision to prescribe IV antibiotics for patients who might
otherwise have been admitted. However, the seven EDs
studied are part of a regional healthcare system, and beds at
all six hospitals are available to physicians at site A. Indeed,
approximately 20% of such subjects presenting to site A
were admitted to one of the other acute care hospitals. Site
A evidenced the lowest hospitalization rate of all sites,
although this may be attributed to differences in case mix
rather than a greater propensity to prescribe IV agents. The
higher use of IV antibiotics at site A remained, even when
severity of illness was controlled for in the multivariable
analysis. However, it appears the nature of site A (lack of
readily available inpatient beds) may be an important
consideration, given that physicians treating subjects at both
sites A and B were significantly more likely to prescribe IV
antibiotics to subjects at site A. Further, the heterogeneity
in the types of centers sampled (eg, free-standing ED, vs
attached to an acute care hospital) allowed for the
determination of a range of IV antibiotic use which might
be expected in the treatment of CAP.
The decreased use of IV antibiotics during the second
year of data collection highlights a limitation of this study.
Collection of this data coincided with implementation at all
study sites of the critical pathway to guide clinicians in the
management of both inpatients and outpatients with CAP.
This included quarterly performance reviews, which may
have resulted in the decreased use of IV antibiotics as the
study progressed. Inclusion of the study-year variable in
the multivariable analysis controlled for this environmental
factor, however, such intervention limits the generalizability
of our findings. Specifically, receipt of IV antibiotics among
outpatients with CAP in EDs may be more widespread than
reported here.
Not all subjects had radiographic confirmed pneumonia.
Rather, these data reflect physicians’ practice patterns in
treating suspected or presumed pneumonia. Limiting the
analysis to subjects with radiographic confirmed pneumonia
did not change study conclusions (data not shown). In
addition, it is unclear, from these data, whether the decision
regarding site of care (hospital vs community) preceded the
decision to prescribe IV antibiotics or vice versa. If the
decision to treat a subject as an outpatient preceded the
prescribing decision, IV antibiotics may be considered part
of an efficacious outpatient regimen. Alternately, IV
antibiotics may have been employed as a means to stabilize
and/or further assess “borderline” cases prior to making a
decision regarding hospitalization. Both of these approaches
may be beneficial: the former in providing improved
treatment outcomes and preventing subsequent
hospitalization, the latter in preventing unnecessary initial
hospitalizations. Further study of both of these approaches
to treatment would assist in determining the efficacy and
efficiency of employing IV antibiotics for CAP in the ED.
Finally, this study did not include a comprehensive
follow-up of outpatients. Differences in outcome between
the different routes of administration and study sites and
the effect of decreased use of IV agents in the second year
of the study are unknown. Thus, we cannot comment upon
the appropriateness of IV antibiotic use. Judicious use of
IV antibiotics for treatment of CAP in EDs may prevent
costly hospitalization, as noted above; however, further study
Table 3 Predictors of receipt of IV antibiotic in the emergency
department: results of multivariable analysis
Patient variable Odds ratio 95% CI
Study year (second) 0.37 0.26–0.52
Temperature (units = 1 °C) 1.68 1.43–1.96
Respirations per minute (units = 5) 1.23 1.06–1.43
Vomiting 1.61 1.07–2.45
Residence (Personal care home) 5.30 2.71–10.34
Prior antibiotic treatment 1.99 1.33–2.98







Severity: High (triage = 1 or 2) 3.15 1.55–6.38
Moderate (triage = 3) 1.29 0.88–1.90
Low (triage = 4 or 5) 1.00 referent
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is required to determine optimal use of this therapeutic
alternative.
In summary, only a small proportion of outpatients
received IV antibiotics for treatment of CAP in EDs,
although the extent of such practice differed between
hospital sites. A number of severity-related variables were
associated with an increased probability of receipt of IV
agents, however, differences between hospital sites persisted
despite controlling for differences in case mix. While an
initial dose of IV antibiotics in the ED has been suggested
as part of an outpatient management strategy (Moran 2001),
further study is required to determine the extent to which
such use may prevent unnecessary hospitalization, and
improve outcomes.
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